Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,511 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer.
George DJ, Agarwal N, Ramaswamy K, Klaassen Z, Bitting RL, Russell D, Sandin R, Emir B, Yang H, Song W, Lin Y, Hong A, Gao W, Freedland SJ. George DJ, et al. Among authors: agarwal n. Prostate Cancer Prostatic Dis. 2024 Apr 2. doi: 10.1038/s41391-024-00815-1. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38565911
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel.
Cheng HH, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan UN, Agarwal N, Heath EI, Pal SK, Rehman HT, Leiter A, Batten JA, Montgomery RB, Galsky MD, Antonarakis ES, Chi KN, Yu EY. Cheng HH, et al. Among authors: agarwal n. Prostate Cancer Prostatic Dis. 2015 Jun;18(2):122-7. doi: 10.1038/pcan.2014.53. Epub 2015 Jan 20. Prostate Cancer Prostatic Dis. 2015. PMID: 25600186 Free PMC article.
An Evolving Role for AXL in Metastatic Renal Cell Carcinoma.
Hahn AW, George DJ, Agarwal N. Hahn AW, et al. Among authors: agarwal n. Clin Cancer Res. 2021 Dec 15;27(24):6619-6621. doi: 10.1158/1078-0432.CCR-21-3029. Epub 2021 Oct 1. Clin Cancer Res. 2021. PMID: 34598944
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.
Penson DF, Armstrong AJ, Concepcion RS, Agarwal N, Olsson CA, Karsh LI, Dunshee CJ, Duggan W, Shen Q, Sugg J, Haas GP, Higano CS. Penson DF, et al. Among authors: agarwal n. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):363-365. doi: 10.1038/s41391-021-00465-7. Epub 2021 Oct 7. Prostate Cancer Prostatic Dis. 2022. PMID: 34621011 Free PMC article. Clinical Trial.
Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.
Penson DF, Armstrong AJ, Concepcion RS, Agarwal N, Olsson CA, Karsh LI, Dunshee CJ, Duggan W, Shen Q, Sugg J, Haas GP, Higano CS. Penson DF, et al. Among authors: agarwal n. Prostate Cancer Prostatic Dis. 2022 Sep;25(3):597. doi: 10.1038/s41391-021-00477-3. Prostate Cancer Prostatic Dis. 2022. PMID: 34848822 Free PMC article. No abstract available.
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study).
George DJ, Agarwal N, Sartor O, Sternberg CN, Tombal B, Saad F, Miller K, Constantinovici N, Guo H, Reeves J, Jiao X, Sandström P, Verholen F, Higano CS, Shore N. George DJ, et al. Among authors: agarwal n. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):306-313. doi: 10.1038/s41391-021-00488-0. Epub 2022 Feb 21. Prostate Cancer Prostatic Dis. 2022. PMID: 35190653 Free PMC article.
External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer.
Swami U, Sayegh N, Jo Y, Haaland B, McFarland TR, Nussenzveig RH, Goel D, Sirohi D, Hahn AW, Maughan BL, Goldkorn A, Agarwal N. Swami U, et al. Among authors: agarwal n. Mol Cancer Ther. 2022 Dec 2;21(12):1857-1861. doi: 10.1158/1535-7163.MCT-22-0020. Mol Cancer Ther. 2022. PMID: 36198026 Clinical Trial.
2,511 results